Yonalink, PSP Enable Faster EHR-to-EDC Data Exchange in Japan

Why It Matters

The partnership streamlines clinical data flow, reducing costs and timelines for sponsors while strengthening Japan’s role as a hub for global drug development. It also demonstrates how cloud imaging and integration technology can accelerate trial efficiency worldwide.

Key Takeaways

• Yonalink and PSP integrate EHR data directly into EDC
• Automation reduces manual entry, boosting trial data accuracy
• PSP's cloud PACS covers 68 million patients, 450 million scans
• Yonalink expands to Japan, first Asian market entry
• Collaboration accelerates global trials, leveraging Japan's robust infrastructure

Pulse Analysis

The bottleneck of moving patient information from hospital electronic health records into trial‑specific electronic data capture systems has long hampered study speed and data quality. Manual transcription not only inflates operational costs but also introduces transcription errors that can jeopardize regulatory compliance. By creating a seamless, automated bridge between EHRs and EDC platforms, Yonalink and PSP address a critical pain point, enabling sponsors to capture real‑world clinical data at the point of care and feed it directly into trial databases.

PSP brings a mature, cloud‑based PACS infrastructure that already supports more than 68 million patients and 450 million imaging examinations across 2,500 Japanese facilities. Its secure, scalable environment provides the backbone for rapid data retrieval and storage. Yonalink complements this with proprietary integration engines that map diverse EHR schemas to the data models of leading EDC solutions, eliminating the need for custom middleware. The synergy allows Japanese hospitals to participate in multinational studies without additional IT overhead, accelerating enrollment and ensuring that high‑quality, standardized data reaches sponsors faster.

Beyond the immediate operational gains, the alliance signals a broader shift toward digital harmonization in clinical research. As more regions adopt similar EHR‑to‑EDC pipelines, sponsors can design globally synchronized trials, reducing duplicate data collection and shortening time‑to‑market for new therapies. For patients, faster, more accurate data handling translates into quicker access to innovative treatments and improved safety monitoring. The Yonalink‑PSP model therefore sets a precedent for how cloud imaging, AI, and integration technologies can collectively elevate the efficiency and impact of global drug development.